Chicago Partners Investment Group’s Teva Pharmaceuticals TEVA Stock Holding History

Chicago Partners Investment Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,825	Closed	-$36K	–	852
2018 Q3	$36K	Buy	1,825 +600	+49%	+$13.9K	0.01%	575
2018 Q2	$30K	Buy	+1,225	New	+$25K	﹤0.01%	580
2017 Q4	–	Sell	-248	Closed	-$4K	–	953
2017 Q3	$4K	Buy	+248	New	+$5.58K	﹤0.01%	892
2016 Q4	–	Sell	-320	Closed	-$15K	–	560
2016 Q3	$15K	Hold	320	–	–	0.01%	386
2016 Q2	$16K	Hold	320	–	–	0.01%	328
2016 Q1	$17K	Hold	320	–	–	0.01%	310
2015 Q4	$21K	Hold	320	–	–	0.01%	338
2015 Q3	$18K	Hold	320	–	–	0.01%	298
2015 Q2	$19K	Sell	320 -27	-8%	-$1.67K	0.01%	304
2015 Q1	$20K	Buy	347 +27	+8%	+$1.57K	0.01%	291
2014 Q4	$18K	Buy	+320	New	+$17.8K	0.01%	301

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Chicago Partners Investment Group's TEVA Position: Q4 2018 in Review

Chicago Partners Investment Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 1,825 shares — an estimated $36K sold.

Chicago Partners Investment Group first reported a position in TEVA in Q4 2014 and held it in 11 quarters. The position peaked at $36K in Q3 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Chicago Partners Investment Group reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Chicago Partners Investment Group sold 1,825 Teva Pharmaceuticals shares in Q4 2018, an estimated $36K.
Chicago Partners Investment Group first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 11 quarters.
Chicago Partners Investment Group's Teva Pharmaceuticals position peaked at $36K in Q3 2018.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Chicago Partners Investment Group's 13F filing for Q4 2018, filed 11 Jan 2019.